Cipla informs about company updates

23 Jan 2020 Evaluate

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Cipla has informed that the United States Food and Drug Administration (USFDA) has classified the inspection conducted at its Goa manufacturing facility from 16-27 September 2019 as Official Action Indicated (OAI). The Company does not believe that this will have any material impact on the US business at this stage. The Company has a strong track record of maintaining the highest standard of compliance and will work closely with the agency to comprehensively address the observations received.

The above information is a part of company’s filings submitted to BSE.


Cipla Share Price

1490.00 10.40 (0.70%)
29-May-2024 14:26 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1491.35
Dr. Reddys Lab 5996.90
Cipla 1490.00
Zydus Lifesciences 1045.80
Lupin 1607.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.